Published on
Updated
Reading 2 mins.
Faced with the difficulty in finding an effective treatment for triple-negative breast cancer, a new site had the good idea of bringing together on a single platform all the clinical trials in progress in the country. A practical initiative, accessible to all patients.
“Finding the right clinical trial has never been easier”. The catchphrase of the Klineo site does not advance by four paths and it is exactly what women affected by breast cancer, in particular “triple negative breast cancer”, need in search of a treatment. The idea is ingenious and above all very practical: since December 14, the Klineo site has been listing on a single platform all the clinical trials concerning triple negative (but also other cancers) throughout the country to respond to two problems: less than 5% of cancer patients participate in clinical trials, while 20% of trials fail due to lack of recruitment.
The dreaded triple negative breast cancer
If breast cancer is generally a cancer that is cured well, the triple negative which affects 15% of breast cancers remains particularly aggressive and affects in particular women under 40 years of age.
This triple-negative breast cancer includes cancers that show an absence of expression of estrogen and progesterone hormone receptors but also an absence of overexpression of the growth factor HER-2. For these tumors with increased aggressiveness, there is therefore no response to proven treatments: hormone therapy and Herceptin, a treatment for HER-2+ breast cancer.
Faced with this type of tumour, conventional chemotherapy and recently immunotherapy may be options, but with relative effectiveness. According to the Haute Autorité de Santé, the median overall survival for these cancers is 14.5 months.
Having access to all triple-negative breast cancer clinical trials on one platform makes it easier to apply for ongoing studies of promising treatments.
Finding the Right Clinical Trial for Every Patient
Like many online platforms, that of Klineo is surprisingly simple: the patient connects and fills in her medical history. This gives him access to tests compatible with his condition. The patient’s oncologist can also transmit information, and the trial can confirm whether or not to participate, always via the platform. A simplification that can be a game-changer in cancer research and bring hope to patients: according to the site, 70% say they are ready to join a trial.